News + Resources

What They Are Saying: M&A Fuels Investment and Innovation in the American Life Sciences Industry

What They Are Saying: M&A Fuels Investment and Innovation in the American Life Sciences Industry

In the wake of the 43rd J.P. Morgan Healthcare Conference held last week, industry leaders underscored the essential role of mergers and acquisitions (M&A) in fueling America’s life sciences industry. In this annual spotlight on the life sciences industry, M&A and other collaborations were a centerfold focus as a way for companies of all sizes to navigate the long, costly journey to bring new treatments and cures to patients.

read more
Innovations Advanced by M&A: A Breakthrough Precision Therapy for Rare Cancers

Innovations Advanced by M&A: A Breakthrough Precision Therapy for Rare Cancers

Life sciences companies of all sizes rely on mergers and acquisitions (M&A) to focus on what they do best, and then combine complementary resources and expertise to quickly and efficiently advance new treatments and cures to consumers. In the case of Ignyta’s acquisition by Roche, M&A played a pivotal role in accelerating a new precision therapy to patients battling rare forms of cancer.

read more
Innovations Advanced by M&A: New Treatment Options for Migraines

Innovations Advanced by M&A: New Treatment Options for Migraines

For many small and early-stage life science companies, making the leap from research and development (R&D) to manufacturing and distribution of a new treatment can be an insurmountable barrier. Pfizer’s acquisition of Biohaven Pharmaceuticals, for example, accelerated the global distribution of two new migraine therapies, while also allowing the early-stage company to continue pursuing new scientific breakthroughs.  

read more